Open Orphan (LSE:ORPH) advanced 3% to 23.7p on Monday morning after revealing a contract renewal expected to deliver “significant revenue” over the next 12 months. The specialist pharma services...
pharma
Open Orphan expands human challenge trial capacity with new volunteer recruitment centres
Open Orphan (LSE:ORPH) We may have entered a new year, but momentum at Open Orphan continues to build at pace. On Wednesday, the rapidly-growing pharma services firm and AIM darling announced that...
Open Orphan and hVIVO’s human vaccine trial for Covid-19 begins
The first volunteer has been dosed with a COVID-19 vaccine as part of hVIVO’s phase 1 clinical trial of COVI-VAC. Following on from its announcement in July last year, the CRO, part of Open Orphan...
Open Orphan has a great start to 2021 with key 12-month contract renewal
Open Orphan PLC (LSE: ORPH) has recently extended a contract with a top-three global pharma company. Its Venn Life Services subsidiary, operating out of Breda, Netherlands, will provide chemistry,...
Open Orphan wins vaccine contract extension and announces toxicology study completion
Open Orphan (LSE: ORPH) subsidiary Venn Life Sciences has extended a consulting contract with a global pharma firm to support two vaccine development programmes. Venn’s Breda office in the...
“We are scaling-up rapidly and at minimum expense” – Open Orphan’s Cathal Friel on the pharma services firm’s exciting plans for 2021 and beyond
Human challenge study pioneer and AIM darling Open Orphan (LSE:ORPH) is set for a record-breaking 2021. The joint London and Dublin-listed pharma services firm is now profitable for the first...
Open Orphan courts more major pharma backing with £4m RSV contract
Open Orphan (LSE:ORPH) has bagged its second major contract with a top-three global pharmaceutical company in as many months. On Monday, the contract research organization services company revealed...
Special Report: 6 Reasons Why XPhyto Therapeutics Can Enhance Your Portfolio – (CSE:XPHY | OTC:XPHYF | FSE:4XT)
Huge biotech potential at XPhyto Therapeutics (CSE:XPHY | OTC:XPHYF | FSE:4XT) Biotechs are among the most profitable, highest-margin businesses on earth. Why? Exclusivity and first-mover advantage....
XPhyto (CSE:XPHY│OTC:XPHYF) – an exhilarating biotech company with Big Pharma potential!
Have you ever wondered how the Big Pharma companies got so big? Just look at some of their market caps. Roche (SWX:RO) is worth $290 billion. Novartis (SWX:NOVN) is worth $220 billion....